Skip to content

Study · Randomized controlled trial · 2016

2 results

Effects of Nasal Calcitonin vs. Oral Gabapentin on Pain and Symptoms of Lumbar Spinal Stenosis: A Clinical Trial Study.

Haddadi K, Asadian L, Isazade A

Clinical medicine insights. Arthritis and musculoskeletal disorders5 Jul 2016Cited by 14 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In lumbar spinal stenosis patients, calcitonin yielded lower disability scores than gabapentin after three months: 23 ± 12.05 versus 32 ± 16.08 (P ≤ 0.05).

    In plain wordsIn lumbar spinal stenosis patients, calcitonin produced a lower disability score than gabapentin after three months.

    Outcome
    DecreaseOswestry Disability Index
    Study

    n: not reported in source

    Comparator
    Gabapentin
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    200 IU daily · nasal · 8 weeksAs given in this study (human).

    Measurements

    Oswestry Disability Index, mean
    23
    calcitonin group, reported ±12.05
    Oswestry Disability Index, mean
    32
    gabapentin group, reported ±16.08
    p
    ≤ 0.05
    calcitonin vs gabapentin

    Source sentences

    Summary
    After three months of study and after four weeks off the prescription, mean values of Oswestry Disability Index in the calcitonin, gabapentin, and control groups were 23 ± 12.05, 32 ± 16.08, and 38 ± 22.09, respectively (P ≤ 0.05, calcitonin group vs. gabapentin group, and P ≤ 0. 001, calcitonin gro…
    1 context sentence
    Summary · context
    In this clinical trial, 90 patients with symptoms of neurogenic claudication and magnetic resonance imaging-proven LSS were randomly assigned to nasal salmon calcitonin, gabapentin, or placebo treatments for eight weeks (30 participants in each group).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In lumbar spinal stenosis patients, calcitonin yielded lower disability scores than control after three months: 23 ± 12.05 versus 38 ± 22.09.

    In plain wordsIn lumbar spinal stenosis patients, calcitonin produced a lower disability score than placebo after three months.

    Outcome
    DecreaseOswestry Disability Index
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    200 IU daily · nasal · 8 weeksAs given in this study (human).

    Measurements

    Oswestry Disability Index, mean
    23
    calcitonin group, reported ±12.05
    Oswestry Disability Index, mean
    38
    control group, reported ±22.09

    Source sentences

    Summary
    After three months of study and after four weeks off the prescription, mean values of Oswestry Disability Index in the calcitonin, gabapentin, and control groups were 23 ± 12.05, 32 ± 16.08, and 38 ± 22.09, respectively (P ≤ 0.05, calcitonin group vs. gabapentin group, and P ≤ 0. 001, calcitonin gro…
    1 context sentence
    Summary · context
    In this clinical trial, 90 patients with symptoms of neurogenic claudication and magnetic resonance imaging-proven LSS were randomly assigned to nasal salmon calcitonin, gabapentin, or placebo treatments for eight weeks (30 participants in each group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.